Replies to post #269805 on Avid Bioservices Inc (CDMO)

[biopharm]

9-13-16 4:30pm: Speaker: Jeff Hutchins (VP/Prelin.Res., Peregrine), “Overriding Immune Suppression and Increasing TILs Through Blockade of the Phosphatidylserine Signaling Pathway”

Nice to see Jeff Hutchins involved here. There are biotechs that try to remove these TILs and treat them with IL-2 and then re-inject them. It actually sounds like Peregrine has an easy way around this and this saves the patient from traveling back to the hospital at a critical time and hope they are part of a small group that it works on. Overriding Immune Suppression is the key and from biopsies to blood tests... to PS Targeting will certainly shake up many Big Pharmas.

Tumor-infiltrating lymphocytes and interleukin-2 (IL-2)

Researchers have found immune system cells deep inside some tumors and have named these cells tumor-infiltrating lymphocytes (TILs). These T cells can be removed from tumor samples taken from patients and multiplied in the lab by treating them with IL-2. When injected back into the patient, these cells can be active cancer fighters.

Treatments using TILs are being tested in clinical trials in people with melanoma, kidney cancer, ovarian cancer, and other cancers. Early studies of this approach by researchers from the National Cancer Institute have been promising, but its use may be limited because doctors might not be able to get TILs from all patients.

Last Medical Review: 07/23/2015
Last Revised: 11/05/2015

http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/immunotherapy/immunotherapy-whats-new-immuno-res

----------

NIH study demonstrates that a new cancer immunotherapy method could be effective against a wide range of cancers

May 8, 2014

In ACT, a patient’s own TILs are collected, and those with the best antitumor activity are grown in the laboratory to produce large populations that are infused into the patient. However, prior to this work it had not been clear whether the human immune system could mount an effective response against mutant proteins produced by epithelial cell cancers. These cells comprise more than 80 percent of all cancers. It was also not known whether such a response could be used to develop personalized immunotherapies for these cancers.
..
..
The researchers first did whole-exome sequencing, in which the protein-coding regions of DNA are analyzed to identify mutations that the patient’s immune cells might recognize. Further testing showed that some of the patient’s TILs recognized a mutation in a protein called ERBB2-interacting protein (ERBB2IP). The patient then underwent adoptive cell transfer of 42.4 billion TILs, approximately 25 percent of which were ERBB2IP mutation-reactive T lymphocytes, which are primarily responsible for activating other cells to aid cellular immunity, followed by treatment with four doses of the anticancer drug interleukin-2 to enhance T-cell proliferation and function.

Following transfer of the TILs, the patient’s metastatic lung and liver tumors stabilized. When the patient’s disease eventually progressed, after about 13 months, she was re-treated with ACT in which 95 percent of the transferred cells were mutation-reactive T cells, and she experienced tumor regression that was ongoing as of the last follow up (six months after the second T-cell infusion). These results provide evidence that a T-cell response against a mutant protein can be harnessed to mediate regression of a metastatic epithelial cell cancer.

“Given that a major hurdle for the success of immunotherapies for gastrointestinal and other cancers is the apparent low frequency of tumor-reactive T cells, the strategies reported here could be used to generate a T-cell adoptive cell therapy for patients with common cancers,” said Rosenberg.
..
..
https://www.nih.gov/news-events/news-releases/nih-study-demonstrates-new-cancer-immunotherapy-method-could-be-effective-against-wide-range-cancers

Now this is important and as I understand it, the good TILs are separated out and are the ones the MD's are trying to multiply... BUT what about the rest (which naturally also have flipped PS)! Naturally they can't target those flipped PS cells because Peregrine has all the rights/patents to targeting flipped PS ... so what do they do? They PRIME it.. (they call it..) and actually sending in a big dosage of chemotherapy to kill as much as the flipped PS cells as possible...

Well, we can all see what is happening. TROUBLE .. and flipped PS must be targeted and I hope Jeff Hutchins make this as clear as day and then we can avoid other biotechs trying to work their way around all those flipped PS cells.

FDA halts cancer immunotherapy trial after 3 patient deaths

July 8, 2016

..
..

CEO Hans Bishop revealed that the two patients, along with an additional patient in May, died as the result of cerebral edema -- brain swelling caused by the presence of excessive fluid. Investigators, he said, pinpointed the likely culprit to be the addition of fludarabine to the pre-conditioning regimen, a one-time primer for treatment. In this particular course of treatment, pre-conditioning consists of a heavy dose of chemotherapy to kill off existing cancer cells in order to give the new, cancer-killing T-cells room to grow. It's like hitting a reset button to restart the immune system.
..
..
Fludarabine, Bishop explained, had shown to increase efficacy in previous studies, which is why the decision was made to add it to the pre-conditioning regimen in this particular trial. But an unforeseen interaction between fludarabine and the JCAR015 cells proved to be lethal.
..

http://www.cnn.com/2016/07/08/health/cancer-immunotherapy-trial-deaths-juno-therapeutics/